To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on the incidence of DGF in recipients of kidneys of donation after circulatory death (DCD) and donation after brain death (DBD) donors
Objective: To compare the effect of a sevoflurane based anaesthesia versus a propofol based anaesthesia on the incidence of delayed graft function in recipients of DCD and DBD donor kidneys. Study design: Prospective randomized controlled European multicentre clinical trial with two parallel groups Study population: Patients ≥18 years scheduled for kidney transplantation with a kidney from a DBD or DCD donor Intervention: Patients will be included and randomised to one of the following groups: Group 1 PROP (control): Propofol: a propofol-remifentanil based anaesthesia. Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based anaesthesia. Main study parameters: Primary outcome: The two co-primary endpoints are the incidence of DGF and one-year acute rejection in recipients of DCD and DBD donor kidneys. DGF is defined as need for dialysis within the first week after transplantation, excluding one-time dialysis for hyperkalaemia. Acute rejection is defined by the modified BANFF 2013 classification and must be associated with decline in kidney function and treatment. Secondary outcomes Functional delayed graft function (fDGF) is defined as the absence of a daily decrease of at least 10% in serum creatinine for at least three consecutive days; primary non function (PNF) defined as a permanent lack of function of the allograft; length of hospital stay and postoperative complications of all kind (28). Estimated glomerular filtration rate (eGFR) at one week and three and twelve months calculated with the CKD-EPI formula; measured GFR employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo) at twelve months; readmissions at three and twelve months, graft survival and patient survival at twelve months.; The investigators predefined four substudies being: Cardiac biomarkers in renal transplantation, Volatile vs Intravenous anaesthetic agent; Predictive value of urinary Biomarkers in a deceased donor kidney transplantation cohort to predict PNF, DGF, Acute rejection and long term graft function and outcome; Association between intraoperative haemodynamics and vasopressor use and graft outcome; Postoperative delirium, volatile vs Intravenous anaesthetic agent (Groningen, Aarhus);
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
488
General anesthesia with sevoflurane
General anesthesia with propofol
Aarhus University Hospital
Aarhus, Denmark
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
Amsterdam University Medical Center
Amsterdam, Netherlands
university Hospital Oslo
Oslo, Norway
Fundagio Puigvert
Barcelona, Spain
Incidence of delayed graft function and/or one year acute rejection
DGF is defined as need of dialysis first 7 days after transplantation Acute rejection up to 1 year after transplantation, defined by the modified BANFF 2013 classification and must be associated with decline in kidney function and treatment.
Time frame: DGF: 7 days after transplantation Acute rejection: up to 1 year after transplantation
Estimated Glomerular Filtration Rate (GFR)
calculated with the CKD-EPI formula
Time frame: 7 days after transplantation, 3 months after transplantation, 1 year after transplantation
incidence of primary non function (PNF)
PNF is defined as permanent lack of function of the transplanted kidney. This kidney will not gain function after transplantation
Time frame: up to 3 months after transplantation
Incidence of funactional Delayed Graft Function
Absence of a daily decrease of at least 10% in serum creatinine for at least three consecutive days
Time frame: 7 days after transplantation
Length of hospital stay
Days
Time frame: From day of transplantation until the day of discharge, assessed up to 60 days
Postoperative complications of all kind
Time frame: from the day of transplantation until the day of discharge, assessed up to 60 days
hospital readmissions after transplantation
Time frame: 3 months after transplantation and between 3 months and 1year after transplantation
Graft survival
Time frame: up to 1 year after transplantation
All-cause mortality
Mortality due to any cause
Time frame: up to 1 year after transplantation
measured GFR employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo) at twelve months
In a subpopulation of Groningen, Aarhus, Oslo; employing Iodinethalamate (Groningen), CrEDTA (Aarhus) and Iohexol (Oslo)
Time frame: 1 year after transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.